After release of Q1 earnings report.
Share price on the rise.
Richter awarded for Cariprazine.
European Medicines Agency is not a bearer of bad news only.
Slashes target price, removes Esmya from model.
Negative impact on 2017 profits.
Profit of Hungary's leading drugs maker plunges.
Earnings report expected to show profit contraction.
Government to support the sector.
One of key products under EMA investigation.
After robust Q3 figures.
Profit greatly beats expectations.
Regardless of rouble trouble.
Signs exclusive distribution agreement with Prima-Temp.
For the commercialisation of novel drug in Europe, Latin America and other markets.
As of 1 August.
Despite profit plunge.
Earnings report to be published this week.